ALVR Projected Dividend Yield
AlloVir Inc ( NASDAQ : ALVR )AlloVir is a late clinical-stage cell therapy company developing allogeneic T-cell therapies to treat and prevent devastating viral diseases. Co.'s Pipeline includes: Posoloeucel, which is an allogeneic, off-the-shelf virus-specific T cell (VST) therapy candidate targeting adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus that can lead to devastating viral disease in the allogeneic hematopoietic cell transplant population; and ALVR106, which is an allogeneic, off-the-shelf VST therapy candidate developed to target devastating diseases caused by human metapneumovirus, influenza, parainfluenza virus and respiratory syncytial virus. 21 YEAR PERFORMANCE RESULTS |
ALVR Dividend History Detail ALVR Dividend News ALVR Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |